Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Final CTU new 2019 masthead1

Contraceptive Technology Update – August 1, 2006

August 1, 2006

View Archives Issues

  • New pill options give women choices while changing menstrual bleeding

    The Food and Drug Administration (FDA) has just given approval to Seasonique (Duramed Pharmaceuticals; Pomona, NY), an extended-regimen oral contraceptive (OC).
  • New research emerges on NuvaRing contraceptive

    Women who switch to the NuvaRing contraceptive vaginal ring (Organon, Roseland, NJ) from other forms of hormonal contraception experience reduced hormone-related adverse events, according to results from a study presented at the recent European Society of Contraception in Istanbul, Turkey.1
  • Look at LNG IUS for menorrhagia treatment

    Your next patient is a 35-year-old mother of two who is experiencing ongoing heavy menstrual bleeding (menorrhagia). Recently remarried, she says she may want to have a child in the future with her new partner. What are your treatment options?
  • Male contraceptive options in the pipeline

    For years, the much talked-about male contraceptive pill has remained tantalizingly out of reach. What if the first contraceptive method to reach the commercial market relied on a nonhormonal approach instead?
  • Science investigates contraceptive gels

    When discussing spermicides with prospective users, family planning providers in the United States have only nonoxynol-9 (N-9) formulations in the contraception arsenal. What if there were other formulations added to the mix?
  • Study looks at weight impact on OC efficacy

    Research findings have suggested higher failure rates in oral contraceptive (OC) users who are heavy; however, new results from a retrospective analysis of Phase III efficacy data of a popular ethinyl estradiol/norgestimate formulation (Ortho Tri-Cyclen Lo, Ortho McNeil Pharmaceutical; Raritan, NJ) indicate that it is not associated with an increased risk of pregnancy in such women.
  • Contraceptive options for overweight women

    Unplanned pregnancies carry extra health risks for obese women. In a 2005 study, researchers found that overweight women (BMI 25-29.9) had increased risks of diabetes, hypertension, pre-eclampsia, and cesarean delivery, with even higher risks for obese women (BMI 30 and above).